130 related articles for article (PubMed ID: 2223395)
1. Adoptive cellular therapy.
Urba WJ; Longo DL
Cancer Chemother Biol Response Modif; 1990; 11():265-80. PubMed ID: 2223395
[No Abstract] [Full Text] [Related]
2. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
Kurnick JT; Kradin RL
Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
[No Abstract] [Full Text] [Related]
3. Clinical use of interleukin-2 in treating cancer.
Patterson DL; Wiemann MC
Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
[No Abstract] [Full Text] [Related]
4. [Quality control of biological therapy in patients with tumors].
Zhang S
Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):483-4. PubMed ID: 9275493
[No Abstract] [Full Text] [Related]
5. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
6. [Cellular immunotherapy of cancer].
Kawakami Y
Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813
[No Abstract] [Full Text] [Related]
7. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
Oldham RK
Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
[No Abstract] [Full Text] [Related]
8. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
West WH
Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
[No Abstract] [Full Text] [Related]
9. Lymphokine-activated killer lymphocytes: extramural clinical trials.
Sniecinski IJ
Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
[No Abstract] [Full Text] [Related]
10. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
Wolf JA; Grimm EA
Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968
[No Abstract] [Full Text] [Related]
11. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cellular therapy.
Sznol M; Urba WJ
Cancer Chemother Biol Response Modif; 1991; 12():213-30. PubMed ID: 1931444
[No Abstract] [Full Text] [Related]
13. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
Clark J; Longo DL
Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
[No Abstract] [Full Text] [Related]
15. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
Nitta T
No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
[No Abstract] [Full Text] [Related]
16. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
Pierce WC; Belldegrun A; Figlin RA
Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
[No Abstract] [Full Text] [Related]
17. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
Thompson JA; Benyunes MC; Bianco JA; Fefer A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
[No Abstract] [Full Text] [Related]
18. [Immunotherapy of malignant melanoma].
Flageul B; Miclea JM; Bensussan A; Degos L
Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
[No Abstract] [Full Text] [Related]
19. [Treatment of metastatic melanoma with interleukin-2].
Chosidow O; Guillaume JC
Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
[No Abstract] [Full Text] [Related]
20. Clinical/technical challenges in adoptive cellular immunotherapy: in vitro culture techniques.
Yannelli JR; Jadus MR; Beckner S; Lacerna LV; Oldham RK
Immunol Ser; 1989; 48():191-206. PubMed ID: 2488322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
